Global Pain Management Drugs Market 2018-2022 - Strong Pipeline and Recently Approved Drugs to Boost Demand - Technavio
LONDON--(BUSINESS WIRE)--Jan 4, 2019-- analysts forecast the global pain management drugs market to grow at a CAGR of nearly 4% during the forecast period, according to their latest market research report.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190104005199/en/
Technavio has published a new market research report on the global pain management drugs market from 2018-2022. (Photo: Business Wire)
Novel drug delivery systems and novel targets for pain management is one of the major trends being witnessed in the . New drug delivery systems are supporting the rate-controlled and target-specific methods over conventional routes and are expected to lead to further advancements in pain management treatment options. New opioid delivery techniques comprises of intravenous infusions, patient-controlled dispensing systems, time-release transdermal skin patches, oral transmucosal preparations nasal sprays and inhaled aerosols, as well as intrathecal and epidural delivery.
According to Technavio analysts, one of the key factors contributing to the growth of the global pain management drugs market is the strong pipeline and recently approved pain management drugs:
Global pain management drugs market: Strong pipeline and recently approved pain management drugs
During the forecast period, most of the therapeutics that are in the last stage of development are expected to get marketing approval. Pipelines for most common pain conditions are chronic pain, post-operative pain, acute pain, low back pain, osteoarthritis, migraine headache, and others. Pain management pipelines have different studies for testing newer targeted drugs for chronic pain. The extensive variety of drugs in the development phase includes braclykinin antagonists, opioid receptor ligands, microsomal prostaglandin E synthase-1 (mPGES-1), substance P and neurokinin receptor antagonists, glutamate receptor antagonists, ATP-gated ionotropic P2X2 receptors antagonists, nitric oxide-based analgesics, and norepinephrine transporter inhibitors.
According to a senior analyst at Technavio for research on central nervous system, “The launch of monoclonal antibodies such as nerve growth factor, calcitonin gene-related peptide, and interleukin 6 inhibitors, and novel abuse-deterrent opioids will drive the growth of the global pain management drugs market during the forecast period.”
Global pain management drugs market: Segmentation analysis
The global pain management drugs market research report provides market segmentation by product (opioids, NSAIDs, and others), by pain types (nociceptive pain, neuropathic pain, and psychogenic pain), and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
The opioids segment held the largest market share in 2017, accounting for 41% of the market. This product segment is expected to dominate the global market throughout the forecast period.
The Americas led the market in 2017 and the region is expected to dominate the market through 2022, with nearly 2% increase in its market share.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20190104005199/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2019.
PUB: 01/04/2019 10:50 AM/DISC: 01/04/2019 10:50 AM